home
Author : admin

Doctor William Hearl appointed as the Director of HLB

HLB announced that they appointed Doctor William Hearl, CEO of Immunomic Therapeutics (IT) as director of HLB. On February 27th, HLB announced that they decided to invest in and acquire IT in order to secure a new anti-cancer pipeline and expand its stake to 51% in the future to promote IPO to Nasdaq or Kosdaq. William Hearl, the founder and CEO of IT, is a doctor of biochemistry from the University of Tennessee, a biotech expert dedicated to the development of a wide range of therapeutics, including HIV and hepatitis C treatments, at global pharmaceutical companies and research institutes such as Electro Nucleonics for over 20 years.


 


Doctor Hearl said "I am very proud to be part of the HLB that is driving the success of the Rivoceranib," and said. "I will make the most of my experience and knowledge to help HLB grow into a global biopharmaceutical group."


 


The anti-cancer drug development pipeline and royalty revenue through commercialization of allergy treatment are expected to further enhance HLB's position as a global bio company.